Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Jacksonville, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
706
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Jacksonville, FL
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Mayo Clinic, Jacksonville, FL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 445–456 of 706 matching trials with a site at Mayo Clinic, Jacksonville, FL.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning

NCT06200116
Status at this site: Recruiting
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Aug 21, 2026, 10:01 PM EDT
Active, not recruiting Phase 2 Interventional

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

NCT05607004
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Neoplasms, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions
(Z)-endoxifen, goserelin
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 7, 2026, 9:07 AM EDT
Active, not recruiting Phase 2 Interventional

Allogeneic BM-MSCs in Patients With Painful Lumbar Facet Arthropathy

NCT06001853
Site status not listed — check the official record
View directory record Official record
Conditions
Facet-Mediated Low Back Pain, Lumbar Facet Joint Osteoarthritis
Interventions
BM-MSC injection, DSMO Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 30, 2026, 2:43 AM EDT
Recruiting Not applicable Interventional

Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

NCT05378347
Status at this site: Recruiting
View directory record Official record
Conditions
Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder), Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder)
Interventions
Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis, Medtronic Endurant II or Endurant IIs Stent Graft System
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
20 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
32
States / cities
Loma Linda, California • Newport Beach, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 8:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT03331198
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 5:10 AM EDT
Active, not recruiting Phase 3 Interventional

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia
Interventions
Chemotherapy, Placebo, Quizartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
52
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 6:55 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

NCT06111235
Site status not listed — check the official record
View directory record Official record
Conditions
Bladder Cancer, Non Muscle Invasive Bladder Cancer, Urologic Cancer, Urothelial Carcinoma
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Drug · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
90
States / cities
Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 31, 2026, 1:28 PM EDT
Active, not recruiting Phase 3 Interventional

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

NCT03488693
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
No Radiation, Radiation
Other · Radiation
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
35 Years and older · Female only
Enrollment
2,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
451
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 8:11 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

NCT03012100
Site status not listed — check the official record
View directory record Official record
Conditions
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Placebo Administration, Sargramostim
Drug · Other · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 14, 2026, 2:01 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

HAIQU (Hospital AIr QUality)

NCT07670117
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Respiratory Tract Infection
Interventions
Self-swab test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Aug 5, 2026, 4:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

NCT05377996
Status at this site: Recruiting
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Breast Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Triple Negative Breast Cancer
Interventions
Emi-Le
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 14, 2026, 6:15 AM EDT
Recruiting No phase listed Observational

Clinical Outcome Measure at Stryker Spine

NCT06226272
Status at this site: Recruiting
View directory record Official record
Conditions
Degenerative Disc Disease, Degenerative Scoliosis
Interventions
Spinal Deformities Correction, Spinal Fusion
Device
Lead sponsor
VB Spine, LLC
Industry
Eligibility
18 Years and older
Enrollment
5,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
7
States / cities
Jacksonville, Florida • Scarborough, Maine • Southfield, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Aug 1, 2026, 11:42 PM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Jacksonville, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.